~~<i id='D1E7691432'><strike id='D1E7691432'><tt id='D1E7691432'><pre id='D1E7691432'></pre></tt></strike></i>~~

00:00

00:00 00:00 LIVE

buffering

Replay

knowledge

entertainment

author：Wikipedia 2025-08-28 08:47:10 - browse：389

Aduhelm, a pioneering treatment for Alzheimer’s disease that collapsed under corporate mistakes and regulatory controversy, is now a cautionary tale in pharmaceutical history.

This week Biogen said it would no longer sell or study the medicine, which first won approval in 2021, ending an era for one of biotech’s storied companies and leaving the rest of the industry to piece together the lessons of a would-be blockbuster that never took off.

STAT reporters took a stab at the Aduhelm legacy — for biotech, Biogen, and Alzheimer’s research — on a recent episode of the Readout LOUD. Here’s an edited transcript of that conversation.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Hollywood unions extend contract negotiations for actors
Next article： Some top drug companies are starting to take action on climate

knowledge

hotspot

knowledge

focus

hotspot

MichelleMonje/StanfordUniversity/NIHTocagen(TOCA)saidTuesdaythataPhase3clinicaltrialinvolvinganovelg

WSS

2023 Nobel Prize in Medicine goes to Karikó and Weissman

2023 Nobel Prize in Medicine goes to Karikó and Weissman

FDA sees ‘potential systemic bias’ in Amgen’s KRAS drug trial

What will Novo Nordisk's VC do with its influx of cash?

Hospitals struggle to profit from CAR

Tocagen's brain cancer gene therapy trial continues. Investors worry

knowledge

entertainment

knowledge

Trump demands the U.S. pay no more for drugs than other countries … again

Why Congress must ban federal programs from using QALYs

Tori Bowie and the unacceptable rates of Black maternal death

WHO recommends second malaria vaccine

After affirmative action ruling, medical educators look to 'holistic review'

Setback for rare diseases as Taysha Gene Therapies pulls back

ChatGPT in medicine: STAT answers readers' burning questions

With Roe v Wade overturned, abortion providers work to adapt

The high cost of giving birth even with insurance

Study identifies new proteins linked to dementia risk 25 years later

hotspot

Study identifies new proteins linked to dementia risk 25 years later

Why Congress must ban federal programs from using QALYs

Readout Newsletter: Biotech news, Wall Street disappointment, Lilly's drug delays

Congress extends some pandemic preparedness programs

Hospitals struggle to profit from CAR

6 solutions to address cancer drug shortages and others

knowledge

focus

focus

hotspot